Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BioRestorative Therapies, Inc.

Get SEC filing alerts via email and in your feed for BioRestorative Therapies, Inc.

BRTX

BioRestorative Therapies, Inc.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. develops cell-based therapeutic products primarily using adult stem cells for regenerative medicine. Its core programs target chronic lower back pain via BRTX-100, an autologous mesenchymal stem cell therapy for disc and spine conditions, and metabolic disorders through the ThermoStem platform using brown adipose-derived stem cells. The company also operates a biocosmeceuticals segment offering cell-based aesthetic products. It focuses on minimally invasive treatments with proprietary technology and clinical-grade manufacturing.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BioRestorative Therapies, Inc.

1
1
BioRestorative Therapies, Inc. BioRestorative Therapies Reports Q1 2026 Financial Results with Revenue Decline and Improved Net Loss

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
BioRestorative Therapies, Inc. BioRestorative Therapies Reports $14.2 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
BioRestorative Therapies, Inc. BioRestorative Therapies Reports $3M Net Loss and Declining Revenue in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BioRestorative Therapies, Inc. BioRestorative Therapies Reports Revenue Growth but Significant Net Loss in Latest 10-Q Filing

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BioRestorative Therapies, Inc. BioRestorative Therapies Reports Revenue Decline and Increased Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BioRestorative Therapies, Inc. BioRestorative Therapies Reports $8.98 Million Net Loss, Revenue Growth to $401,000

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
BioRestorative Therapies, Inc. BioRestorative Therapies Reports Improved Financials, Reduced Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments